Canaccord raised the firm’s price target on Insulet (PODD) to $353 from $331 and keeps a Buy rating on the shares. The firm said Insulet beat revenue estimates across the board and confidently raised its guidance for FY25, with strength expected across all markets and populations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet Corporation Reports Strong Q2 2025 Growth
- Insulet’s Earnings Call Highlights Robust Growth and Optimism
- Insulet’s Strong Financial Performance and Optimistic Outlook Justify Buy Rating
- Insulet’s Strong Market Position and Growth Potential Justify Buy Rating with Increased Price Target
- Morgan Stanley ups Insulet price target, says pressed its advantage in Q2